Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Novel therapeutics in supportive cancer treatment

Novel therapeutics in supportive cancer treatment Summary With constantly improving cancer therapies, patient’s quality of life, the management of potential side effects and treatment-related symptoms have also made considerable progress. Chemotherapy-induced nausea and vomiting (CINV) still constitutes a major problem for many patients. New developments in the field allow a more comfortable administration of guideline-based antiemetic therapy and may further improve the control of nausea. Therapeutic options for the cancer anorexia–cachexia syndrome (CACS), common in advanced cancers, are still limited and hampered by numerous side effects. Among these, targeting the ghrelin-receptor pathway could be a novel approach; however, data are still immature. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Novel therapeutics in supportive cancer treatment

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/novel-therapeutics-in-supportive-cancer-treatment-RNVP0hBYxd
Publisher
Springer Journals
Copyright
2017 Springer-Verlag GmbH Austria
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-017-0353-1
Publisher site
See Article on Publisher Site

Abstract

Summary With constantly improving cancer therapies, patient’s quality of life, the management of potential side effects and treatment-related symptoms have also made considerable progress. Chemotherapy-induced nausea and vomiting (CINV) still constitutes a major problem for many patients. New developments in the field allow a more comfortable administration of guideline-based antiemetic therapy and may further improve the control of nausea. Therapeutic options for the cancer anorexia–cachexia syndrome (CACS), common in advanced cancers, are still limited and hampered by numerous side effects. Among these, targeting the ghrelin-receptor pathway could be a novel approach; however, data are still immature.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Sep 1, 2017

References

  • 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
    F Roila, A Molassiotis, J Herrstedt
  • A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy
    RJ Gralla, SM Bosnjak, A Hontsa
  • Pharmacological mechanism of 5‑HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting
    C Rojas, BS Slusher
  • Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
    R Gralla, M Lichinitser, S Der Vegt
  • Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy randomized, comparative phase III trial
    M Saito, K Aogi, I Sekine
  • A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
    MS Aapro, SM Grunberg, GM Manikhas
  • Inhibition of substance P‑mediated responses in NG108–15 cells by netupitant and palonosetron exhibit synergistic effects
    M Stathis, C Pietra, C Rojas
  • Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study
    PJ Hesketh, G Rossi, G Rizzi
  • A randoized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy
    M Aapro, H Rugo, G Rossi
  • NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron
    M Aapro, M Karthaus, L Schwartzberg
  • Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials
    BL Rapoport, MR Chasen, C Gridelli
  • Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial
    LS Schwartzberg, MR Modiano, BL Rapoport
  • Olanzapine for the prevention of chemotherapy-induced nausea and vomiting
    RM Navari, R Qin, KJ Ruddy
  • Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial
    RM Navari, SE Gray, AC Kerr
  • Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial
    M Abe, Y Hirashima, Y Kasamatsu
  • Understanding the mechanisms and treatment options in cancer cachexia
    K Fearon, J Arends, V Baracos
  • Prognostic effect of weight loss prior to chemotherapy in cancer patients
    WD Dewys, C Begg, PT Lavin
  • Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis
    KC Fearon, AC Voss, DS Hustead
  • Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer
    TW LeBlanc, RD Nipp, CN Rushing
  • Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment
    CM Prado, VE Baracos, LJ McCargar
  • Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
    PJ Ross, S Ashley, A Norton
  • ESPEN guidelines on nutrition in cancer patients
    J Arends, P Bachmann, V Baracos
  • Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials
    JS Temel, AP Abernethy, DC Currow
  • Megestrol acetate for treatment of anorexia-cachexia syndrome
    V Ruiz Garcia, E López-Briz, R Carbonell Sanchis, JL Gonzalvez Perales, S Bort-Marti
  • Systematic review of the treatment of cancer-associated anorexia and weight loss
    T Yavuzsen, MP Davis, D Walsh, S LeGrand, R Lagman
  • Corticosteroid therapy of preterminal gastrointestinal cancer
    CG Moertel, AJ Schutt, RJ Reitemeier, RG Hanh
  • Clinical evaluation and optimal management of cancer cachexia
    A Tuca, P Jimenez-Fonseca, P Gascón
  • Glucocorticoidlike activity of megestrol. A summary of Food and Drug Administration experience and a review of the literature
    M Mann, E Koller, A Murgo, S Malozowski, J Bacsanyi, M Leinung
  • The role of ghrelin in anorexia-cachexia syndromes
    B Guillory, A Splenser, J Garcia
  • Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials
    JM Garcia, RV Boccia, CD Graham
  • ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small cell lung cancer (NSCLC) patients with cachexia
    D Currow, JS Temel, A Abernethy, J Milanowski, J Friend, KC Fearon